Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2021 Filed Feb 8, 2021 19:59 UTC |
Parham Richelle PDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004334 · form4.xml · derivative · entry 2 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 Underlying: Common Stock · 986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 19:59 UTC |
Parham Richelle PDirector
|
Exercise / conversionCommon Stock | 986 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004334 · form4.xml · nonDerivative · entry 1 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 19:58 UTC |
NEUPERT PETER MDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004332 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 Underlying: Common Stock · 986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 19:58 UTC |
NEUPERT PETER MDirector
|
Exercise / conversionCommon Stock | 986 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004332 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 19:57 UTC |
Kong GarhengDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004331 · form4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 Underlying: Common Stock · 986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 19:57 UTC |
Kong GarhengDirector
|
Exercise / conversionCommon Stock | 986 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004331 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 19:56 UTC |
Gilliland Dwight GaryDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004330 · form4.xml · derivative · entry 2 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 Underlying: Common Stock · 986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 19:56 UTC |
Gilliland Dwight GaryDirector
|
Exercise / conversionCommon Stock | 986 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004330 · form4.xml · nonDerivative · entry 1 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 19:55 UTC |
Davis Jeffrey A.Director
|
Exercise / conversionRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004328 · form4.xml · derivative · entry 2 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 Underlying: Common Stock · 986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 19:55 UTC |
Davis Jeffrey A.Director
|
Exercise / conversionCommon Stock | 986 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004328 · form4.xml · nonDerivative · entry 1 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 19:53 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004326 · form4.xml · derivative · entry 3 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 Underlying: Common Stock · 986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 19:53 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionCommon Stock | 986 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004326 · form4.xml · nonDerivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 01:40 UTC |
Kong GarhengDirector
|
GrantRestricted Stock Unit · Derivative | 771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004075 · form4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 Underlying: Common Stock · 771 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:28 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantNon-qualified Stock Options · Derivative | 8,000 | $0.00 Strike: $233.39 | $0.00 |
DisclosureSEC source: 0001127602-21-004019 · form4.xml · derivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2031-02-01 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:28 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantRestricted Stock Unit · Derivative | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004019 · form4.xml · derivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,926 Underlying: Common Stock · 2,300 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:26 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
GrantNon-qualified Stock Options · Derivative | 2,500 | $0.00 Strike: $233.39 | $0.00 |
DisclosureSEC source: 0001127602-21-004016 · form4.xml · derivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2031-02-01 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:26 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
GrantRestricted Stock Unit · Derivative | 710 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004016 · form4.xml · derivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,467 Underlying: Common Stock · 710 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:18 UTC |
Schechter Adam HDirector · President & CEO
|
GrantNon-qualified Stock Options · Derivative | 29,000 | $0.00 Strike: $233.39 | $0.00 |
DisclosureSEC source: 0001127602-21-004011 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2031-02-01 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:18 UTC |
Schechter Adam HDirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 8,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004011 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,854 Underlying: Common Stock · 8,320 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:17 UTC |
Caveney Brian JEVP, President of Diagnostics
|
GrantNon-qualified Stock Options · Derivative | 4,600 | $0.00 Strike: $233.39 | $0.00 |
DisclosureSEC source: 0001127602-21-004008 · form4.xml · derivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires 2031-02-01 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:17 UTC |
Caveney Brian JEVP, President of Diagnostics
|
GrantRestricted Stock Unit · Derivative | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004008 · form4.xml · derivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,538 Underlying: Common Stock · 1,330 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:15 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
GrantNon-qualified Stock Options · Derivative | 3,100 | $0.00 Strike: $233.39 | $0.00 |
DisclosureSEC source: 0001127602-21-004006 · form4.xml · derivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,100 Underlying: Common Stock · 3,100 shares Expires 2031-02-01 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:15 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
GrantRestricted Stock Unit · Derivative | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004006 · form4.xml · derivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,658 Underlying: Common Stock · 890 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:14 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
GrantNon-qualified Stock Options · Derivative | 4,600 | $0.00 Strike: $233.39 | $0.00 |
DisclosureSEC source: 0001127602-21-004004 · form4.xml · derivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires 2031-02-01 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:14 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
GrantRestricted Stock Unit · Derivative | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004004 · form4.xml · derivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,932 Underlying: Common Stock · 1,330 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:13 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
GrantNon-qualified Stock Options · Derivative | 4,600 | $0.00 Strike: $233.39 | $0.00 |
DisclosureSEC source: 0001127602-21-004002 · form4.xml · derivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires 2031-02-01 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:13 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
GrantRestricted Stock Unit · Derivative | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004002 · form4.xml · derivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,831 Underlying: Common Stock · 1,330 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:11 UTC |
Seltz Judith CEVP, CHRO
|
GrantNon-qualified Stock Options · Derivative | 2,300 | $0.00 Strike: $233.39 | $0.00 |
DisclosureSEC source: 0001127602-21-004000 · form4.xml · derivative · entry 2 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Underlying: Common Stock · 2,300 shares Expires 2031-02-01 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:11 UTC |
Seltz Judith CEVP, CHRO
|
GrantRestricted Stock Unit · Derivative | 660 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004000 · form4.xml · derivative · entry 1 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 660 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 18:22 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantNon-qualified Stock Options · Derivative | 1,200 | $0.00 Strike: $233.39 | $0.00 |
DisclosureSEC source: 0001127602-21-003925 · form4.xml · derivative · entry 2 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 1,200 shares Expires 2031-02-01 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 18:22 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantRestricted Stock Unit · Derivative | 350 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003925 · form4.xml · derivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,684 Underlying: Common Stock · 350 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:10 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
GrantNon-qualified Stock Options · Derivative | 2,300 | $0.00 Strike: $233.39 | $0.00 |
DisclosureSEC source: 0001127602-21-003997 · form4.xml · derivative · entry 2 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Underlying: Common Stock · 2,300 shares Expires 2031-02-01 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:10 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
GrantRestricted Stock Unit · Derivative | 660 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003997 · form4.xml · derivative · entry 1 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Underlying: Common Stock · 660 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 18:18 UTC |
Williams R SandersDirector
|
GrantRestricted Stock Unit · Derivative | 771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003923 · form4.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 Underlying: Common Stock · 771 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 18:17 UTC |
Parham Richelle PDirector
|
GrantRestricted Stock Unit · Derivative | 771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003921 · form4.xml · derivative · entry 1 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 Underlying: Common Stock · 771 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 18:12 UTC |
Gilliland Dwight GaryDirector
|
GrantRestricted Stock Unit · Derivative | 771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003918 · form4.xml · derivative · entry 1 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 Underlying: Common Stock · 771 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 18:16 UTC |
NEUPERT PETER MDirector
|
GrantRestricted Stock Unit · Derivative | 771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003920 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 Underlying: Common Stock · 771 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 18:11 UTC |
Davis Jeffrey A.Director
|
GrantRestricted Stock Unit · Derivative | 771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003917 · form4.xml · derivative · entry 1 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 Underlying: Common Stock · 771 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 18:10 UTC |
BELINGARD JEAN-LUCDirector
|
GrantRestricted Stock Unit · Derivative | 771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003916 · form4.xml · derivative · entry 1 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 Underlying: Common Stock · 771 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 18:09 UTC |
ANDERSON KERRII BDirector
|
GrantRestricted Stock Unit · Derivative | 771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003915 · form4.xml · derivative · entry 3 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 Underlying: Common Stock · 771 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest fully on February 2, 2022. F3 · derivative.expiration_date: The Restricted Stock Units vest fully on February 2, 2022. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 17:11 UTC |
Williams R SandersDirector
|
Exercise / conversionNon-qualified Stock Options · Derivative | 1,300 | $0.00 Strike: $98.49 | $0.00 |
DisclosureSEC source: 0001127602-21-002786 · form4.xml · derivative · entry 3 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,300 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Director stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2008 Stock Incentive Plan. F2 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 17:11 UTC |
Williams R SandersDirector
|
Exercise / conversionCommon Stock | 1,300 | $98.49 | $128,037.00 |
DisclosureSEC source: 0001127602-21-002786 · form4.xml · nonDerivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2020 Filed Feb 4, 2021 18:09 UTC |
ANDERSON KERRII BDirector
|
GiftCommon Stock | 746 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003915 · form4.xml · nonDerivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,894 F1 · balance_after: Amount reflects annuity payment of 480 shares made by the reporting person's grantor retained annuity trust to the reporting person on September 23, 2020. Read SEC document |
| December 01, 2020 Filed Dec 14, 2020 23:04 UTC |
Davis Jeffrey A.Director
|
Exercise / conversionRestricted Stock Unit · Derivative | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-031299 · form4.xml · derivative · entry 2 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986 Underlying: Common Stock · 173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on 12/1/2020. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on 12/1/2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| December 01, 2020 Filed Dec 14, 2020 23:04 UTC |
Davis Jeffrey A.Director
|
Exercise / conversionCommon Stock | 173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-031299 · form4.xml · nonDerivative · entry 1 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 15:48 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
SaleCommon Stock | 588 | $214.59 | $126,178.92 |
DisclosureSEC source: 0001127602-20-028554 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,949.3789 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 14:19 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028414 · form4.xml · derivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,501 Underlying: Common Stock · 2,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 5, 2020. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 5, 2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 14:19 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 835 | $214.42 | $179,040.70 |
DisclosureSEC source: 0001127602-20-028414 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,537.3789 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 149.0224 shares acquired on June 30, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 14:19 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionCommon Stock | 2,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-028414 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,372.3789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 149.0224 shares acquired on June 30, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 14:21 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028415 · form4.xml · derivative · entry 3 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,208 Underlying: Common Stock · 2,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 5, 2020. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 5, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.